BioMarin Pharmaceutical (BMRN) On FDA Acceptance For VOXZOGO And The Valuation Case
BioMarin Pharmaceutical (BMRN) stock is back in focus after the FDA accepted the company’s supplemental New Drug Application for VOXZOGO, a key regulatory step toward potential full approval in achondroplasia.
See our latest analysis for BioMarin Pharmaceutical.
At a share price of US$58.87, BioMarin Pharmaceutical has seen a 10.7% 90 day share price return, while the 1 year total shareholder return has declined 1.5%, suggesting recent momentum contrasts with weaker longer term results.
If this VOXZOGO update has you thinking about broader healthcare opportunities, it could be a good moment to scan other potential ideas in 39 healthcare AI stocks
For BioMarin Pharmaceutical, a 10.7% gain over 90 days alongside softer multi year returns could point to either a business story catching up with the share price, or sentiment simply swinging around a familiar narrative on VOXZOGO. How does today’s valuation stack up against that backdrop?
Most Popular Narrative: 33% Undervalued
With BioMarin Pharmaceutical shares at $58.87 versus a narrative fair value of $87.85, the current setup hinges on how investors view VOXZOGO and the broader rare disease pipeline.
Strong year over year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top line revenue growth. Accelerated pipeline advancement, including late stage programs (BMN 333 for achondroplasia, BMN 401 for ENPP1 deficiency, and label expansions for PALYNZIQ), positions BioMarin to capitalize on growing patient pools through earlier and more accurate genetic identification, which should expand future addressable markets and boost revenue.
Curious what sits behind that gap between price and fair value? The core of this narrative revolves around faster earnings expansion and a valuation multiple that needs to compress meaningfully over time. The tension lies in how growth, margins, and risk are balanced to reach that outcome.
Result: Fair Value of $87.85 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, BioMarin Pharmaceutical’s story could change quickly if pricing pressure in rare disease treatments intensifies, or if key pipeline programs face regulatory setbacks or delays.
Find out about the key risks to this BioMarin Pharmaceutical narrative.
Another View: BioMarin Pharmaceutical on Earnings Multiples
That 33% gap to narrative fair value sits beside a very different signal from earnings multiples. BioMarin Pharmaceutical trades on a P/E of 42.3x, compared with 32.1x for peers and 16.5x for the wider US Biotechs group. The fair ratio is 27.9x, which suggests valuation risk if sentiment cools.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of optimism and caution around BioMarin Pharmaceutical, this is a good time to review the data yourself and decide where you stand. To balance the potential upside with the concerns already on investors’ radar, make sure you understand the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond BioMarin Pharmaceutical?
If BioMarin Pharmaceutical has sharpened your interest, do not stop here. Broaden your watchlist with other focused stock ideas that could suit different goals.
- Target potential mispricings by reviewing companies screened as 38 high quality undervalued stocks to see which ones might deserve a closer look.
- Strengthen your income focus with businesses highlighted in the 7 dividend fortresses and see which yields currently stand out.
- Prioritize resilience by scanning the 79 resilient stocks with low risk scores and spot stocks where risk indicators look relatively contained.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com